Achieve Life Sciences misses Q4 earnings, shares fall

Published 11/03/2025, 20:40
Achieve Life Sciences misses Q4 earnings, shares fall

SEATTLE - Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported fourth quarter earnings that fell short of analyst expectations, sending shares down 4.9% in response. The late-stage pharmaceutical company, focused on developing cytisinicline for smoking cessation, posted a quarterly loss of $0.36 per share, $0.02 worse than the consensus estimate of a $0.34 loss.

For the fourth quarter, Achieve Life Sciences reported total operating expenses of $12.2 million and a net loss of $12.4 million. The company ended 2024 with $34.4 million in cash, cash equivalents, and marketable securities.

Despite the earnings miss, Achieve Life Sciences reiterated its plans to submit a new drug application (NDA) for cytisinicline to the U.S. Food and Drug Administration by the end of the second quarter of 2025. The company has completed enrollment in its ORCA-OL long-term exposure trial, meeting the requirement of 300 participants receiving six months of cumulative cytisinicline treatment needed for the NDA submission.

"We are thrilled with our progress to date and excited to have the NDA submission on track for the end of next quarter, furthering our mission to bring cytisinicline to market as the first new FDA-approved nicotine dependence treatment in nearly 20 years," said Rick Stewart, Achieve’s Chief Executive Officer.

The company also announced positive outcomes from two data safety monitoring committee reviews of the ORCA-OL trial, with no safety concerns identified. Additionally, Achieve Life Sciences recently appointed two new board members and a new Chief Financial Officer to support its strategic initiatives and potential commercialization efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.